ProCE Banner Activity

Phase III BELINDA Trial of Tisagenlecleucel vs Standard of Care as Second-line Treatment for R/R Aggressive B-Cell Non-Hodgkin Lymphoma

Slideset Download
Conference Coverage
In the phase III BELINDA trial, tisagenlecleucel as second-line therapy in patients with R/R aggressive B-cell NHL had no significant impact on event-free survival vs standard of care.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation